[
 {
  "title": "Insight into Lipidology",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Research into lipidology has provided insight into patient cases and thinking about lipids. This research has spanned across various fields including clinical, nutrition, genetics, and drug research.",
  "content_length": 199,
  "content_tokens": 35,
  "embedding": []
 },
 {
  "title": "Understanding Dyslipidemia and Interventions",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Being more informed about dyslipidemia and the interventions used can reduce the risk of atherosclerotic disease, cerebrovascular disease, and peripheral vascular disease.",
  "content_length": 171,
  "content_tokens": 34,
  "embedding": []
 },
 {
  "title": "Discussion on Atherosclerosis",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "The pathogenesis of atherosclerosis and how early it begins is a topic of discussion. The role of chronic inflammation in atherosclerosis is also considered.",
  "content_length": 157,
  "content_tokens": 31,
  "embedding": []
 },
 {
  "title": "Lipidology and Heart Disease",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "The 'battle' between LDL particle size and particle number, the use of statins, and why niacin may have been unjustly dismissed as a therapeutic option are all topics of interest in the study of heart disease.",
  "content_length": 209,
  "content_tokens": 45,
  "embedding": []
 },
 {
  "title": "HDL Paradox and Heart Disease Risk",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "The HDL paradox is a phenomenon where drugs that raise HDL-C seem to elevate (or have little impact on) heart disease risk.",
  "content_length": 123,
  "content_tokens": 27,
  "embedding": []
 },
 {
  "title": "Mendelian Randomization and PCSK9 Inhibitors",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Mendelian randomization, natureâ€™s randomized trial, and how PCSK9 inhibitors work and why they may be underutilized are also topics of discussion.",
  "content_length": 146,
  "content_tokens": 35,
  "embedding": []
 },
 {
  "title": "Preventing Cardiovascular Disease",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "The latest in diagnostic imaging, blood pressure, metabolic health, and more.",
  "content_length": 77,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Pros and Cons of GLP-1 Weight Loss Drugs and Metformin",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on the pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent.",
  "content_length": 99,
  "content_tokens": 26,
  "embedding": []
 },
 {
  "title": "Understanding Atherosclerosis",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Atherosclerosis is a multifocal, smoldering, immunoinflammatory disease of medium-sized and large arteries fuelled by lipids. The pathogenesis of atherosclerosis, the different stages of atherosclerosis, and when heart disease begins are discussed.",
  "content_length": 248,
  "content_tokens": 53,
  "embedding": []
 },
 {
  "title": "Risk Factors for Heart Disease",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on the biggest risk factor for heart disease and the difference between cholesterol, lipoproteins, LDL-C, LDL-P, and ApoB.",
  "content_length": 133,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "Role of LDL in Heart Disease",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on whether LDL causes heart disease, taking into account time, and magnitude, of exposure of LDL concentrations.",
  "content_length": 123,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Use of Statins",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on the use of statins, their adverse effects, and their role in reducing events, possibly by improving endothelial health and/or reducing inflammation.",
  "content_length": 162,
  "content_tokens": 31,
  "embedding": []
 },
 {
  "title": "Role of Inflammation in Atherosclerosis",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on the role of chronic inflammation in atherosclerosis and the potential benefits of reducing inflammation.",
  "content_length": 118,
  "content_tokens": 19,
  "embedding": []
 },
 {
  "title": "Use of Niacin in Treatment",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on why niacin may have been unjustly dismissed as a therapeutic option and its effects on HDL.",
  "content_length": 105,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Understanding Lp(a)",
  "date": "July 2, 2018",
  "context": "Cholesterol",
  "people": "Peter Attia",
  "content": "Discussion on Lp(a) and how statins and PCSK9 inhibitors can affect LDL-C and LDL-P.",
  "content_length": 84,
  "content_tokens": 26,
  "embedding": []
 }
]